Hummingbird Bioscience Initiated Phase II Cancer Trial
The study tests a HER3-targeting drug in combination with cetuximab for advanced squamous cell cancers.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you trust artificial intelligence to play a central role in the discovery of new medicines?
Hummingbird Bioscience has launched a Phase II clinical trial, designated NCT05910827, to evaluate the experimental drug HMBD-001 in combination with the EGFR inhibitor cetuximab. The trial is currently recruiting patients with advanced squamous cell cancers across China, Australia, Moldova, and Singapore.
Why it matters
The study targets the dependency of squamous cell carcinomas on HER3 and EGFR signaling pathways to promote tumor growth. By combining these therapies, the researchers aim to deliver an effective, chemo-free treatment option for patients with advanced disease.
The trial utilizes HMBD-001 alongside the EGFR inhibitor cetuximab to dually target HER3 and EGFR signaling, following the identification of recommended doses for expansion during prior study phases.
The players
Hummingbird Bioscience
A biotech company that uses its AIMM platform to discover and develop precision therapeutics for cancers.
Merck KGaA
A global science and technology company that provides cetuximab for this clinical trial collaboration.
The details
HMBD-001 is a therapeutic agent designed to inhibit HER3, a member of the EGFR family of receptors that often drives tumor cell proliferation. The study combines this agent with cetuximab—a monoclonal antibody that binds to and inhibits EGFR—to disrupt multiple survival pathways simultaneously. Hummingbird Bioscience uses its proprietary AIMM platform to identify and enrich the patient population most likely to respond to the combination therapy.
Timeline
September 30, 2026: Hummingbird Bioscience announced the start of Phase II trials.
The Tech Race
This study follows a competitive trend of developing combination therapies to bypass resistance mechanisms in squamous cell carcinomas. It marks a significant milestone in validating the efficacy of HER3 inhibition alongside established EGFR-targeting agents.
This trial is currently open to eligible patients with advanced squamous cell cancers in China, Australia, Moldova, and Singapore. The drug remains in the clinical research stage and is not available for public use or commercial prescription.
The takeaway
The initiation of NCT05910827 marks a shift toward chemo-free, targeted combinations for squamous cancers. Observers should track subsequent updates regarding the recommended dosage expansion results and primary completion status.
Further reading
For more on the current clinical landscape for oncological therapies, see Biotech.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust artificial intelligence to play a central role in the discovery of new medicines?
